Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01121536
Registration number
NCT01121536
Ethics application status
Date submitted
5/05/2010
Date registered
12/05/2010
Date last updated
21/09/2018
Titles & IDs
Public title
Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Query!
Scientific title
A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Query!
Secondary ID [1]
0
0
2009-016648-38
Query!
Secondary ID [2]
0
0
C10953/3074
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Depression
0
0
Query!
Condition category
Condition code
Mental Health
0
0
0
0
Query!
Depression
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Armodafinil
Experimental: Armodafinil 150-200 mg/day - Participants began taking armodafinil at a dosage of 50 mg/day; the dosage was increased by 50 mg/day on days 2 and 4, up to a dosage of 150 mg/day. At the discretion of the investigator, the dosage of armodafinil may be increased to 200 mg/day on day 6 or thereafter, and reduced to 150mg/day if the higher dose is not well tolerated. Treatment was administered for six months.
Treatment: Drugs: Armodafinil
Armodafinil tablets, taken orally, once daily in the morning
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Participants With Treatment-Emergent Adverse Events (TEAE)
Query!
Assessment method [1]
0
0
AEs were graded by the investigator for severity on a three-point scale: mild, moderate and severe. Causality is graded as either related or not related. A serious adverse event (SAE) is an AE resulting in death, a life-threatening adverse event, hospitalization, a persistent or significant disability/incapacity, a congenital anomaly/birth defect, or an important medical event that may require medical intervention to prevent any of the previous results.
Protocol-defined adverse events requiring expedited reporting included skin rash, hypersensitivity reaction, emergent suicidal ideation or suicide attempt, and psychosis.
Query!
Timepoint [1]
0
0
Day 1 up to Month 6
Query!
Primary outcome [2]
0
0
Participants With Clinically Significant Abnormal Serum Chemistry Values
Query!
Assessment method [2]
0
0
Summary of serum chemistry tests in which at least one participant had a during study value that was clinically significant abnormal. The test name and criterion for clinically significant abnormal appear in each row.
ULN=upper limit of normal
BUN=Blood Urea Nitrogen; Uric acid has a normal range of 125-494 µmol/L. Criterion for clinically significant abnormal are different for men and women.
GGT = gamma-glutamyl transpeptidase with a normal range of 4-61 U/L
ALT = alanine aminotransferase with a normal range of 6-43 U/L
BUN = blood urea nitrogen with a normal range of 1.4-8.6 mmol/L
AST = aspartate aminotransferase with a normal range of 9-36 U/L
Query!
Timepoint [2]
0
0
Day 1 to Month 6
Query!
Primary outcome [3]
0
0
Participants With Clinically Significant Abnormal Hematology Values
Query!
Assessment method [3]
0
0
Summary of hematology tests in which at least one participant had a during study value that was clinically significant abnormal. The test name and criterion for clinically significant abnormal appear in each row.
ULN=upper limit of normal
WBC - white blood cell counts with a normal range of 3.8-10.7 10^9/L.
Hemoglobin with a normal range of 115-181 g/L
Hematocrit with a normal range of 0.34-0.54 L/L
Platelet counts with a normal range of 130-400 10^9/L
ANC= absolute neutrophil counts with a normal range of 1.96-7.23 10^9/L
Query!
Timepoint [3]
0
0
Day 1 to Month 6
Query!
Primary outcome [4]
0
0
Participants With Clinically Significant Abnormal Urinalysis Values
Query!
Assessment method [4]
0
0
Summary of urinalysis tests in which at least one participant had a during study value that was clinically significant abnormal. Criterion for clinically significant abnormal urinalysis tests was >=2 unit increase from baseline.
Query!
Timepoint [4]
0
0
Day 1 to Month 6
Query!
Primary outcome [5]
0
0
Participants With Clinically Significant Abnormal Vital Signs Values
Query!
Assessment method [5]
0
0
Summary of vital signs tests in which at least one participant had a during study value that was clinically significant abnormal. Criterion for clinically significant abnormal vital signs are based on FDA Neuropharmacological Division criteria:
Pulse high: >=120 beats per minute (bpm) and increase of >=15 bpm from baseline
Pulse low: <=50 bpm and decrease of >=15 bpm from baseline
Sitting systolic blood pressure high: >=180 mm Hg and increase of >=20 mm Hg from baseline
Sitting systolic blood pressure low: <=90 mm Hg and decrease of >=20 mm Hg from baseline
Sitting diastolic blood pressure high: >=105 mm Hg and increase of >=15 mm Hg from baseline
Sitting diastolic blood pressure low: <=50 mm Hg and decrease of >=15 mm Hg from baseline
Query!
Timepoint [5]
0
0
Day 1 to Month 6
Query!
Primary outcome [6]
0
0
Change From Baseline to Endpoint in Electrocardiogram (ECG) Values
Query!
Assessment method [6]
0
0
ECG was conducted at baseline which was before the first dose of study drug in the double-blind study, and at the month-6 visit of the open-label study (or early termination).
RR= inter-beat intervals
Query!
Timepoint [6]
0
0
Day 0 (baseline), Month 6 or last post-baseline observation
Query!
Primary outcome [7]
0
0
Physical Examination Shifts From Baseline to Endpoint
Query!
Assessment method [7]
0
0
Baseline is the day prior to double-blind treatment. Assessments are summarized as normal or abnormal. The first assessment is the baseline assessment followed by the endpoint assessment. For example 'normal/abnormal' indicates participants who were normal at baseline and abnormal at endpoint.
HEENT = Head, Eye, Ear, Nose and Throat exam
Query!
Timepoint [7]
0
0
Day 0 (baseline), Month 6 (or last post-baseline observation)
Query!
Primary outcome [8]
0
0
Change From Baseline to Endpoint in Body Weight
Query!
Assessment method [8]
0
0
Baseline was the score before the first dose of study drug in the double-blind study.
Query!
Timepoint [8]
0
0
Day 0 (baseline), Month 6 (or last post-baseline observation)
Query!
Primary outcome [9]
0
0
Change From Baseline to Endpoint in the Young Mania Rating Scale (YMRS) Total Score
Query!
Assessment method [9]
0
0
The YMRS is a clinician-rated, 11-item checklist used to measure the severity of manic episodes. Information for assigning scores is gained from the participant's subjective reported symptoms over the previous 48 hours and from clinical observation during the interview. Seven items are ranked 0 through 4 and have descriptors associated with each severity level. Four items (irritability, speech, content, and disruptive-aggressive behavior) are scored 0 through 8 and have descriptors for every second increment. The total scale is 0-60. A score of =12 indicates remission of manic symptoms, and higher scores indicate greater severity of mania. Negative change from baseline scores indicate a decrease in severity of mania.
Baseline was the score before the first dose of study drug in the double-blind study.
Query!
Timepoint [9]
0
0
Day 0 (baseline), Month 6 or last post-baseline observation
Query!
Primary outcome [10]
0
0
Participants With Findings During the Open-Label Study on the Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV)
Query!
Assessment method [10]
0
0
The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The number of participants who had findings on any of the C-SSRS-SLV (SLV=since last visit) categories at any of the time frames are indicated.
- C-SSRS=Columbia Suicide Severity Rating Scale
Query!
Timepoint [10]
0
0
Day 1, Week 1, Months 1, 2, 4 and 6 or last post-baseline visit
Query!
Primary outcome [11]
0
0
Change From Baseline to Endpoint in the Insomnia Severity Index (ISI) Total Score
Query!
Assessment method [11]
0
0
The ISI is a participant-rated, 7-item questionnaire designed to assess the severity of the participant's insomnia. Each item is ranked 0 (none) through 4 (very severe) and has a descriptor associated with each severity level. Total range is 0 (no insomnia) to 28 (very severe insomnia). Responses to each item are added to obtain a total score to determine the severity of insomnia. Negative change from baseline scores indicate a decrease in severity of insomnia. Baseline was the assessment before the first dose of study drug in the double-blind study.
Query!
Timepoint [11]
0
0
Day 0 (baseline), Month 6 (or last post-baseline observation)
Query!
Primary outcome [12]
0
0
Change From Baseline to Endpoint in the Hamilton Anxiety Scale (HAM-A) Total Score
Query!
Assessment method [12]
0
0
HAM-A measures the severity of anxiety symptoms. The scale consists of 14 items, each defined by a series of symptoms, and measures both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Negative change from baseline scores indicate a decrease in severity of anxiety.
Baseline was the score before the first dose of study drug in the double-blind study.
Query!
Timepoint [12]
0
0
Day 0 (baseline), Month 6 or last post-baseline observation
Query!
Secondary outcome [1]
0
0
Change From Baseline to Week 1 and Months 1, 2, 4, 6 and Endpoint in the Total Score From the 30-Item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)
Query!
Assessment method [1]
0
0
The IDS-C30 is a standardized 30-item, clinician-rated scale to assess the severity of a participant's depressive symptoms. Every effort was made to have the same rater evaluate a participant across all visits.
Total scores range from 0-84, with a score of 0 indicating no depression and a score of 84 indicating the most severe depression. Negative change from baseline values indicate improvement in the severity of depression.
Baseline was the score before the first dose of study drug in the double-blind study.
Query!
Timepoint [1]
0
0
Day 0 (baseline), Week 1, Months 1, 2, 4, 6 and the last post-baseline assessment)
Query!
Secondary outcome [2]
0
0
Change From Baseline to Week 1 and Months 1, 2, 4, 6 and Endpoint in the Total Score From the 16-Item Quick Inventory of Depressive Symptomatology-Clinician-Rated (QIDS-C16)
Query!
Assessment method [2]
0
0
The QIDS-C16 was derived from specified items in the IDS-C30, clinician-rated scale to assess the severity of a participant's depressive symptoms. Total scores range from 0-27, with a score of 0 indicating no depression and a score of 27 indicating the most severe depression. Negative change from baseline values indicate improvement in the severity of depression.
Baseline was the score before the first dose of study drug in the double-blind study.
Query!
Timepoint [2]
0
0
Day 0 (baseline), Week 1, Months 1, 2, 4, 6 and the last post-baseline assessment)
Query!
Secondary outcome [3]
0
0
Change From Baseline to Week 1 and Months 1, 2, 4, 6 and Endpoint in the Clinical Global Impression of Severity (CGI-S) for Depression
Query!
Assessment method [3]
0
0
The CGI-S is an observer-rated scale that measures illness severity on a 7-point scale, with the severity of illness scale using a range of responses from 1 (normal) through to 7 (amongst the most severely ill patients). Negative change from baseline values indicate improvement in the severity of depression.
Baseline was the score before the first dose of study drug in the double-blind study.
Query!
Timepoint [3]
0
0
Day 0 (baseline), Week 1, Months 1, 2, 4, 6 and the last post-baseline assessment)
Query!
Secondary outcome [4]
0
0
Change From Baseline to Endpoint in the Global Assessment for Functioning (GAF) Scale
Query!
Assessment method [4]
0
0
The Global Assessment of Functioning (GAF) is a numeric scale (1 through 100) used by mental health clinicians and physicians to rate subjectively the social, occupational, and psychological functioning of adults, e.g., how well or adaptively one is meeting various problems-in-living. Ratings of 1 - 10 mean the participant is in persistent danger of severely hurting self or others (e.g., recurrent violence) or persistent inability to maintain minimal personal hygiene or serious suicidal act with clear expectation of death. Ratings of 91 - 100 indicate no symptoms, and the participant exhibits superior functioning in a wide range of activities, life's problems never seem to get out of hand, is sought out by others because of his or her many positive qualities. Positive change from baseline values indicate improvement in functioning.
Baseline was the score before the first dose of study drug in the double-blind study.
Query!
Timepoint [4]
0
0
Day 0 (baseline), Month 6 or the last post-baseline assessment)
Query!
Eligibility
Key inclusion criteria
Key
- The patient has completed 8 weeks of treatment in a Cephalon-sponsored Phase 3,
double-blind study of armodafinil treatment in patients with major depression
associated with bipolar I disorder.
- The patient met criteria for enrollment in the previous double-blind study and, in the
opinion of the investigator, is in need of continued treatment for depression.
- During the previous double-blind study, the patient must have been taking 1 (or 2) of
the following protocol-allowed mood stabilizers: lithium; valproic acid; olanzapine;
quetiapine; aripiprazole; lamotrigine; risperidone; ziprasidone, (only if taken in
combination with lithium, valproic acid, or lamotrigine). The following criteria must
also be met:
1. The mood stabilizers must be taken in an oral formulation, with the exception of
risperidone, which can be either in an oral or long-acting injection formulation.
2. The patient may be taking 2 protocol-allowed mood stabilizers only if 1 of the
drugs is lithium, valproic acid, or lamotrigine.
3. The patient must be judged by the investigator to be compliant with treatment
with the mood stabilizer(s).
4. The patient must be willing to continue treatment with the same protocol-allowed
mood stabilizer(s) at dosages considered appropriate by the investigator.
- The patient has a Young Mania Rating Scale (YMRS) total score of 14 or less at the
enrollment visit. Patients who have a YMRS score of 12 through 14 must be discussed
with the medical monitor to determine their suitability for enrollment.
Key
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- The patient has any Axis I or Axis II disorder apart from bipolar I disorder that
became the primary focus of treatment during the double-blind study.
- The patient has psychotic symptoms or had psychosis during the double-blind study.
- The patient has current active suicidal ideation, is at imminent risk of self harm, or
has a history of significant suicidal ideation or suicide attempt at any time in the
past that causes concern at present.
- The patient met criteria for alcohol or substance abuse or dependence (with the
exception of nicotine dependence) during the double-blind study.
- The patient has any history of homicidal ideation or significant aggression or
currently has homicidal or significant aggressive ideation.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
30/04/2010
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
31/10/2013
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
867
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Teva Investigational Site 141 - Brisbane
Query!
Recruitment hospital [2]
0
0
Teva Investigational Site 240 - Malvern
Query!
Recruitment postcode(s) [1]
0
0
4053 - Brisbane
Query!
Recruitment postcode(s) [2]
0
0
3144 - Malvern
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Indiana
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Maryland
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Massachusetts
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Mississippi
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Missouri
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New Jersey
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New Mexico
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New York
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
North Carolina
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Ohio
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Oklahoma
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Pennsylvania
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Tennessee
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Texas
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Utah
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Virginia
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Washington
Query!
Country [23]
0
0
Argentina
Query!
State/province [23]
0
0
Buenos Aires
Query!
Country [24]
0
0
Argentina
Query!
State/province [24]
0
0
Cordoba
Query!
Country [25]
0
0
Argentina
Query!
State/province [25]
0
0
La Plata, Buenos Aires
Query!
Country [26]
0
0
Argentina
Query!
State/province [26]
0
0
La Plata
Query!
Country [27]
0
0
Argentina
Query!
State/province [27]
0
0
Rosario
Query!
Country [28]
0
0
Brazil
Query!
State/province [28]
0
0
Rio de Janeiro
Query!
Country [29]
0
0
Bulgaria
Query!
State/province [29]
0
0
Bourgas
Query!
Country [30]
0
0
Bulgaria
Query!
State/province [30]
0
0
Kardzhali
Query!
Country [31]
0
0
Bulgaria
Query!
State/province [31]
0
0
Kazanlak
Query!
Country [32]
0
0
Bulgaria
Query!
State/province [32]
0
0
Pazardjik
Query!
Country [33]
0
0
Bulgaria
Query!
State/province [33]
0
0
Pleven
Query!
Country [34]
0
0
Bulgaria
Query!
State/province [34]
0
0
Plovdiv
Query!
Country [35]
0
0
Bulgaria
Query!
State/province [35]
0
0
Ruse
Query!
Country [36]
0
0
Bulgaria
Query!
State/province [36]
0
0
Sofia
Query!
Country [37]
0
0
Bulgaria
Query!
State/province [37]
0
0
Varna
Query!
Country [38]
0
0
Canada
Query!
State/province [38]
0
0
Kelowna
Query!
Country [39]
0
0
Canada
Query!
State/province [39]
0
0
Mississauga
Query!
Country [40]
0
0
Canada
Query!
State/province [40]
0
0
Penticton
Query!
Country [41]
0
0
Croatia
Query!
State/province [41]
0
0
Rijeka
Query!
Country [42]
0
0
Croatia
Query!
State/province [42]
0
0
Zagreb
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Dole
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Nimes
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Achim
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Dresden
Query!
Country [47]
0
0
Hungary
Query!
State/province [47]
0
0
Budapest
Query!
Country [48]
0
0
Hungary
Query!
State/province [48]
0
0
Nagykallo
Query!
Country [49]
0
0
Italy
Query!
State/province [49]
0
0
Catania
Query!
Country [50]
0
0
Italy
Query!
State/province [50]
0
0
Firenze
Query!
Country [51]
0
0
Italy
Query!
State/province [51]
0
0
Pisa
Query!
Country [52]
0
0
Italy
Query!
State/province [52]
0
0
Rome
Query!
Country [53]
0
0
Poland
Query!
State/province [53]
0
0
Bialystok
Query!
Country [54]
0
0
Poland
Query!
State/province [54]
0
0
Gdansk
Query!
Country [55]
0
0
Poland
Query!
State/province [55]
0
0
Kielce
Query!
Country [56]
0
0
Poland
Query!
State/province [56]
0
0
Krakow
Query!
Country [57]
0
0
Poland
Query!
State/province [57]
0
0
Leszno
Query!
Country [58]
0
0
Poland
Query!
State/province [58]
0
0
Skorzewo
Query!
Country [59]
0
0
Poland
Query!
State/province [59]
0
0
Szczecin
Query!
Country [60]
0
0
Poland
Query!
State/province [60]
0
0
Tuszyn
Query!
Country [61]
0
0
Serbia
Query!
State/province [61]
0
0
Belgrade
Query!
Country [62]
0
0
Serbia
Query!
State/province [62]
0
0
Kragujevac
Query!
Country [63]
0
0
Serbia
Query!
State/province [63]
0
0
Nis
Query!
Country [64]
0
0
Serbia
Query!
State/province [64]
0
0
Novi Knezevac
Query!
Country [65]
0
0
Slovakia
Query!
State/province [65]
0
0
Bratislava
Query!
Country [66]
0
0
Slovakia
Query!
State/province [66]
0
0
Rimavska Sobota
Query!
Country [67]
0
0
Slovakia
Query!
State/province [67]
0
0
Roznava
Query!
Country [68]
0
0
Slovakia
Query!
State/province [68]
0
0
Trencin
Query!
Country [69]
0
0
South Africa
Query!
State/province [69]
0
0
Cape Town
Query!
Country [70]
0
0
South Africa
Query!
State/province [70]
0
0
Centurion
Query!
Country [71]
0
0
South Africa
Query!
State/province [71]
0
0
Johannesburg
Query!
Country [72]
0
0
South Africa
Query!
State/province [72]
0
0
Paarl
Query!
Country [73]
0
0
South Africa
Query!
State/province [73]
0
0
Pretoria
Query!
Country [74]
0
0
Spain
Query!
State/province [74]
0
0
Alcoy
Query!
Country [75]
0
0
Spain
Query!
State/province [75]
0
0
Coslada (Madrid)
Query!
Country [76]
0
0
Spain
Query!
State/province [76]
0
0
Vitoria-Gasteiz
Query!
Country [77]
0
0
Spain
Query!
State/province [77]
0
0
Vitoria
Query!
Country [78]
0
0
Ukraine
Query!
State/province [78]
0
0
Dnipropetrovsk
Query!
Country [79]
0
0
Ukraine
Query!
State/province [79]
0
0
Donetsk
Query!
Country [80]
0
0
Ukraine
Query!
State/province [80]
0
0
Kharkiv
Query!
Country [81]
0
0
Ukraine
Query!
State/province [81]
0
0
Kiev
Query!
Country [82]
0
0
Ukraine
Query!
State/province [82]
0
0
Lugansk
Query!
Country [83]
0
0
Ukraine
Query!
State/province [83]
0
0
Lviv
Query!
Country [84]
0
0
Ukraine
Query!
State/province [84]
0
0
Odessa
Query!
Country [85]
0
0
Ukraine
Query!
State/province [85]
0
0
Poltava
Query!
Country [86]
0
0
Ukraine
Query!
State/province [86]
0
0
S. Oleksandrivka
Query!
Country [87]
0
0
Ukraine
Query!
State/province [87]
0
0
Simferopol
Query!
Country [88]
0
0
Ukraine
Query!
State/province [88]
0
0
Vinnytsya
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Cephalon
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective of this study is to evaluate the safety and tolerability of long term
(6 months) armodafinil treatment as adjunctive therapy to mood-stabilizing medications in
adults with bipolar I disorder.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01121536
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Sponsor's Medical Expert
Query!
Address
0
0
Cephalon
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01121536
Download to PDF